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OBJECTIVES This study was designed to determine the enhancement profile of a necrosis-specific contrast
agent (gadophrin III) in comparison to a standard extracellular agent on T1-weighted
magnetic resonance (MR) images in acute and chronic myocardial infarctions (MIs).
BACKGROUND Contrast-enhanced MR imaging demonstrated the ability to accurately quantify infarct size;
however, some controversies persist about which contrast medium is best suited.
METHODS Fifteen rabbits underwent thoracotomy and permanent occlusion of a branch of the left
coronary artery. Two animals died before imaging, eight were examined 48 h after occlusion
and five animals were imaged six weeks following induction of infarction. All animals received
50 mol/kg of gadophrin-3 24 h before the MR examination. Continuous short-axis views
were collected using an inversion recovery turbo fast low angle shot sequence. Imaging was
repeated 5 to 10 min following additional injection of 100 mol/kg of Magnevist. The area
of hyperenhancement demarcated following gadophrin-3 injection was compared with the
region of hyperenhancement seen on gadophrin-3 plus Magnevist enhanced image using
triphenyltetrazolium chloride (TTC) staining as the standard of reference.
RESULTS In acute MI the mean difference in size of hyperenhancement seen on the two different in vivo
MR scans was1.8 6.0 mm2 (p 0.05). Both measurements showed excellent agreement
with TTC staining. Chronic MIs showed no enhancement with gadophrin-3, whereas
application of Magnevist resulted in hyperenhancement.
CONCLUSIONS Standard extracellular contrast agents do not overestimate the size of acute MI. The
combination of gadophrin-3 and Magnevist can distinguish acute and chronic myocardial
injury because chronic MIs do not enhance with gadophrin-3. (J Am Coll Cardiol 2002;39:
1392–8) © 2002 by the American College of Cardiology Foundation
Assessment of myocardial necrosis is an important issue in
patients with acute myocardial infarction (AMI) because
size, transmurality and reperfusion are known predictors for
outcome and survival (1–3). Left ventricular dysfunction
following AMI can be irreversible when caused by necrosis
with development of scar tissue, or reversible because of
myocardial hibernation or myocardial stunning. Because the
differentiation of reversible from irreversible myocardial
injury influences therapy, there is growing interest in the
prediction of myocardial viability.
Several methods have been used for noninvasive assess-
ment of infarct size and definition of myocardial viability,
including electrocardiogram (ECG) scores, cardiac enzyme
measurements and echocardiographic and scintigraphic im-
aging techniques (4). The search for the optimal imaging
strategy is ongoing, despite limitations including the inabil-
ity to detect small infarctions, low sensitivity or specificity
predicting myocardial viability and low spatial resolution.
In 1980, Goldman et al. (5) discussed the potential
capabilities of cardiac magnetic resonance imaging (MRI).
Given extensive hard- and software improvements over
recent years, cardiac MRI is emerging as an alternative
clinical tool for assessing myocardial infarction (MI). Acute
MI results in increased myocardial signal on transversal
relaxation time (T2)-weighted images. Attempts to use this
property for accurate quantification of infarcted myocar-
dium have largely been disappointing because of a system-
atic overestimation of the area of necrosis (6,7). Other
studies investigated morphologic parameters (such as end-
diastolic wall thickness) for the prediction of myocardial
viability (8,9). These approaches, however, suffered from
low specificity.
Several studies have investigated the ability of contrast-
enhanced MRI to quantify infarct size. Furthermore, a
number of promising MRI techniques have been proposed
for the prediction of myocardial viability (10). However,
some controversies about the most suitable contrast medium
for imaging of MI persist. Whereas Kim et al. (11)
demonstrated that the area of hyperenhancement 5 to 10
min after injection of extracellular contrast agents (such as
gadolinium diethylene-triamino-penta-acetate [Gd-
DTPA]) matches exactly the area of irreversibly damaged
tissue on T1-weighted images, Saeed et al. (12) reported
that these contrast media overestimate the area of necrosis.
For accurate delineation of myocardial necrosis Saeed et al.
(12) suggest the use of necrosis-specific, porphyrin-based
contrast media. They further suggest that any area difference
between the hyperenhanced regions demarcated by standard
and necrosis-specific contrast agents could provide an esti-
mation of potentially salvageable myocardium in the peri-
infarction zone (10,12). To date there are no data available
confirming or disproving this theory.
The aim of our study was to investigate whether the area
of hyperenhancement using extracellular contrast agents is
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larger compared to the region demarcated by porphyrin-
based contrast agents.
MATERIALS AND METHODS
All experimental protocols were performed in accordance
with all state regulations governing animal experiments.
The study was approved by the local “animal experiment”
institutional review board. Myocardial infarction was in-
duced in 15 rabbits (Belgian hare) of either gender (weight
range 3.2 to 4.0 kg). The animals were premedicated with
fentanyl (0.02 mg/kg, Fentanyl-Janssen, Janssen-Cilag,
Neuss, Germany), midazolam (1 mg/kg, Midazolam,
Hoffmann-La Roche, Grenzach-Wyhlen, Germany) and
medetomidin intramuscularly (0.2 mg/kg, Domitor, Pfizer,
Karlsruhe, Germany), anesthetized with propofol intrave-
nously (1.5 mg/kg/min, Propofol Abbott, Abbott, Wiesba-
den, Germany), intubated and mechanically ventilated. A
left-sided thoracotomy was performed in the fourth inter-
costal space. A small incision was made in the pericardium
and a permanent ligature was placed around a branch of the
left coronary artery. The animals were divided into two
groups: in 10 animals (group I) the magnetic resonance
(MR) examination was performed 48 h following occlusion
of the coronary artery for the evaluation of AMI. Animals of
group II (n  5) were imaged six weeks after occlusion of
the coronary artery for evaluation of chronic myocardial
infarction (CMI).
Both Gd-DTPA (Magnevist) and gadophrin-3 were
prepared and supplied by Schering AG (Berlin, Germany).
The necrosis-specific porphyrin-based contrast agent pro-
vides prolonged contrast between normal and pathologic
tissue that last more than 24 h. The contrast between
infarcted myocardium and surrounding tissue is best after a
prolonged delay time, when gadophrin-3 leaves the intra-
vascular space and accumulates in necrotic myocardium.
Therefore, 50 mol/kg of gadophrin-3 were injected into
an ear vein 24 h before imaging. After collection of
continuous gadophrin-3-enhanced short axis views, 100
mol/kg of Magnevist was injected. Imaging was repeated
following a delay time of 5 to 10 min.
All examinations were performed using a 1.5T scanner
(Magnetom Symphony, Siemens Medical Systems, Erlan-
gen, Germany) with a maximum gradient amplitude of 30
mT/m. A segmented k-space inversion recovery turbo fast
low angle shot (IRturboFLASH) sequence designed to
acquire a single high-resolution, strongly T1-weighted im-
age was used for delayed enhancement imaging. Six to eight
3-mm slices without interslice gaps were used to cover the
entire left ventricle. The field of view was reduced to a
minimum of 176 mm. An acquisition matrix of 153  256
(5/8 rectangular field of view) resulted in a pixel size of 0.7
mm  0.7 mm. A single-loop surface coil was used for data
reception.
The IRturboFLASH sequence was optimized for imag-
ing of small animals with a high heart rate (Fig. 1). In
rabbits with an RR interval of about 400 ms, a trigger delay
of 50 ms was used to push the acquisition window into late
diastole. A nonselective inversion pulse was applied follow-
ing the trigger delay. Data acquisition begins following an
inversion time (TI) period which is defined as the time from
the inversion pulse to the center of the acquisition window.
Inversion time was optimized (typically between 180 and
240 ms) for each examination to null the signal of normal
myocardium. The number of gradient echoes per segment
was reduced to nine, resulting in an acquisition time of
about 80 ms per segment, fast enough to make it insensitive
to diastolic cardiac motion. Using a minimum repetition
time (TRmin) of 300 ms, the maximum TI was 260 ms. The
total acquisition time of the sequence amounted to 17
heartbeats (9  17  153 k-space lines).
The effective repetition time (TReff), which influences
image contrast, can be calculated as the mean of the RR
intervals during the measurement. Insufficient detection of
the R-wave of the ECG results in varying repetition time
values during the measurement and decreases image quality.
Therefore, an active ECG system (Siemens Medical Sys-
tems, Erlangen, Germany) with an ECG amplifier next to
the electrodes was used, as well as fiber optic data transmis-
sion. This system reduces ECG signal artifacts induced by
the rapid switching of the gradients and ensured accurate
triggering in all animals.
The animals were sacrificed following completion of the
imaging protocol. The heart was excised and cut into
short-axis slices (slice thickness 3 mm). The sections were
immersed in 2% triphenyltetrazolium chloride (TTC) stain
for 20 min at 37°C. The TTC-stained myocardial slices
were photographed with a digital camera.
All images were transferred to an external workstation.
The area of infarction was measured on TTC-stained as
well as gadophrin-3 and gadophrin-3 plus Magnevist en-
hanced in-vivo images using commercially available soft-
ware (Adobe Photoshop 5.0, Adobe, San Jose, California).
The left ventricular endocardial and epicardial borders were
Abbreviations and Acronyms
AMI  acute myocardial infarction
CMI  chronic myocardial infarction
ECG  electrocardiogram
Gd-DTPA  gadolinium diethylene-triamino-
penta-acetate
IRturboFLASH  inversion recovery turbo fast low
angle shot
MI  myocardial infarction
MR  magnetic resonance
MRI  magnetic resonance imaging
T1  longitudinal relaxation time
T2  transversal relaxation time
TI  inversion time
TReff  effective repetition time
TRmin  minimum repetition time
TTC  triphenyltetrazolium chloride
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traced manually, and hyperenhancement was defined as
signal intensity 3 SDs above the mean of normal myocar-
dium. The MR images were analyzed in a random order by
an observer blind to the TTC data.
The results of the measurements were compared by
calculating systematic and random differences as well as the
correlation coefficient. The agreement between the area of
hyperenhancement on gadophrin-3 and gadophrin-3 plus
Magnevist-enhanced images was illustrated in Bland and
Altman graphs (13). The difference between the two mea-
surements was calculated by subtracting the area of en-
hancement after additional injection of Magnevist from the
area of enhancement following injection of gadophrin-3.
The limits of agreement are provided as the mean  SD.
The mean is the average of the relative differences between
data and is ideally zero, but may be either a positive or
negative value  SD.
RESULTS
Two animals with AMI (group I) died before imaging.
Another two animals showed no area of hyperenhancement
on gadophrin-3 or on gadophrin-3 plus Magnevist-
enhanced in-vivo MR images. In these animals the exper-
imental induction of MI had failed and MI could be
excluded by TTC staining. The remaining six animals of
group I showed hyperenhancement on two slices (n  1),
three slices (n 1), four slices (n 2) and seven slices (n
2), resulting in a total of 27 hyperenhanced slices. The
enhancement of the infarctions was homogenous in all
animals.
The mean difference in size of hyperenhancement demar-
cated by gadophrin-3 and gadophrin-3 plus Magnevist was
1.8  6.0 mm2 (p  0.05, paired t test); the calculated
correlation coefficient was 0.99. Figures 2 and 3 demon-
strate good correspondence between the area of infarction
depicted on TTC staining and the hyperenhanced area seen
on IRturboFLASH image 24 h after injection of
gadophrin-3. The area of hyperenhancement does not
increase following additional injection of a standard extra-
cellular contrast agent. Figure 4 shows the excellent agree-
ment of the two MR measurements plotted in a Bland and
Altman graph.
For the comparison of in-vivo MR images and TTC
staining, slices located at the margins of the infarctions were
excluded in all animals because the evaluation of these slices
may suffer from partial volume effects. The mean difference
of infarction size defined by TTC staining and the area of
hyperenhancement on MR scans was 6.3  10.7 mm2 for
gadophrin-3 and 5.9  13.1 mm2 for gadophrin-3 plus
Magnevist-enhanced images. Both MR measurements
showed no statistically significant difference (p  0.05,
paired t test) compared to TTC staining.
Chronic MIs imaged six weeks following coronary artery
occlusion showed no enhancement following gadophrin-3
injection, whereas application of Magnevist resulted in
hyperenhancement of the infarction zone in all five animals
of group II (Fig. 5). The spatial extend of hyperenhance-
ment using Magnevist was virtually identical to the spatial
extend of scar tissue defined by TTC staining (mean
difference 5.8  9.1 mm2; p  0.05, paired t test).
Figure 1. Acquisition scheme of the segmented inversion recovery turbo fast low angle shot (IRturboFLASH) sequence. AW  acquisition window;
IR  inversion pulse; TD  delay after trigger; TI  inversion time; TReff  effective repetition time; TRmin  minimum repetition time.
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DISCUSSION
This study carries two important messages: 1) in acute
nonreperfused MI the area of hyperenhancement on T1-
weighted IRturboFLASH images following administration
of an extracellular paramagnetic agent is not larger than the
area of hyperenhancement seen on necrosis-specific
gadophrin-3 enhanced images; and 2) six-week-old chronic
MIs do not enhance with necrosis-specific gadophrin-3, but
rather with an extracellular paramagnetic agent.
In contrast to earlier studies (12,14), there was no
evidence for overestimating the size of AMI on the basis of
the enhancement pattern of standard extracellular contrast
agents. In the past various extracellular, intracellular, intra-
vascular and necrosis-specific MR contrast agents have been
evaluated for imaging AMI and CMI (10). To our knowl-
edge, this is the first study comparing extracellular and
necrosis-specific contrast agents in the same animal at the
same time. Coincidence of the two measurements is of great
importance, because the area of necrosis continues to grow
as the peri-infarction zone of potentially salvageable myo-
cardium becomes infarcted (12).
Figure 2. Acute transmural infarction (arrows). The area of hyperenhance-
ment on gadophrin-3 (B) and gadophrin-3 plus Magnevist (C) enhanced
images closely matches the infarction size defined by triphenyltetrazolium
chloride staining (A).
Figure 3. An acute nontransmural infarction (arrows) can clearly be
depicted on triphenyltetrazolium chloride staining (A), gadophrin-3 (B)
and gadophrin-3 plus Magnevist (C) enhanced images. The area of
hyperenhancement is virtually identical on both in-vivo magnetic reso-
nance scans.
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Contrast agents for the assessment of myocardial viability.
In AMI, myocytes lose the ability to exclude standard
extracellular contrast agents such as Gd-DTPA. Therefore
the fractional distribution volume of the contrast agent
increases. This increase can be detected as an area of
hyperenhancement on T1-weighted images. Porphyrin-
based necrosis-specific contrast agents, on the other hand,
directly accumulate in infarcted myocardium (15). Although
the exact mechanism of enhancement remains unknown,
several studies demonstrated that the size of gadophrin-2
Figure 4. Agreement between area of hyperenhancement (mean value of the differences  closed line;  2 SD  dotted lines) from gadophrin-3 and
gadophrin-3 plus Magnevist enhanced T1-weighted images depicted in a Bland and Altman graph. Average value of the two measurements is plotted along
the x-axis; the difference (gadophrin-3 minus gadophrin-3 plus Magnevist) is plotted along the y-axis.
Figure 5. Diastolic (A) and systolic (B) cine magnetic resonance images show thinned myocardium with a lack of systolic wall thickening in an animal with
chronic myocardial infarction. The inversion recovery turbo fast low angle shot sequence shows no enhancement 24 h after injection of gadophrin (C),
whereas the infarcted myocardium (arrows) appears bright following the injection of gadolinium diethylene-triamino-penta-acetate (D).
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(Schering AG) enhanced regions exactly matches the size of
infarct defined by histologic staining (7,16). Gadophrin-3
(Schering AG) is a new porphyrin-based contrast agent. It
differs from gadophrin-2 by the addition of a copper atom to
the center of the phorphyrin system. Physicochemical and
pharmacologic properties of both contrast agents are com-
parable, but the stability of the new contrast agent is
considerably improved.
Saeed et al. (12) suggest the optimal MR contrast media
for sizing of AMI to be characterized by long regional
residence compared with image acquisition, and specific
accumulation within necrotic myocardium, thereby provid-
ing high contrast between infarcted and normal myocar-
dium. The first requirement has been fulfilled by hardware
and software improvements of the MR systems. Magnetic
resonance scanning has been vastly accelerated. Sequences
are now capable of collecting high-resolution ECG-
triggered images within the confines of a single comfortable
breath-hold. Furthermore, new sequence designs have vastly
improved the achievable contrast between infarcted and
normal myocardium following injection of standard extra-
cellular contrast agents. Thus, Simonetti et al. (17) reported
that the contrast to noise level between normal and infarcted
myocardium is about three times higher on segmented
IRturboFLASH sequences compared to standard T1-
weighted spin echo or turbo spin echo sequences.
Some controversies concerning the choice of the most
appropriate contrast agent for defining myocardial necrosis
have persisted, however. Whereas Kim et al. (11) demon-
strated that the area of hyperenhancement following injec-
tion of an extracellular contrast agent exactly matches
irreversibly damaged myocardium, other groups (12,18)
claimed an overestimation of infarction size by extracellular
contrast agents. On the basis of this observation it has been
suggested that the peri-infarction zone of injured but viable
myocardium also enhances with extracellular agents, but not
with necrosis-specific contrast agents. The data of our study
disprove this theory. Histologically verified areas of MI
closely corresponded to areas of hyperenhancement follow-
ing Gd-DTPA injection and were statistically no different
from those exhibiting enhancement following administra-
tion of gadophrin-3.
Methodical considerations. There are several possible
causes for the contradictory results reported in different
animal studies. First, the width of the peri-infarction zone
differs between species. In dogs it can be as wide as 25 mm,
whereas it is only 13 mm in pigs (12). Furthermore, Fieno
et al. (19) demonstrated that differences between hyperen-
hancement seen on MR images and area of infarction
demarcated by TTC staining may be caused by partial
volume effects. Poorer spatial resolution will accentuate
these differences. Therefore, high spatial resolution is crucial
for accurate in-vivo measurements of infarct size. Finally,
differences in the design of sequences (spin-echo vs.
IRturboFLASH) used for imaging of delayed contrast
enhancement may contribute to a variation in the perceived
enhancement patterns. The inversion pulse used to mini-
mize the signal intensity of the normal myocardium can
diminish the latitude of the signal intensities within the
myocardium. Therefore, it might be possible that the
margins of the infarct, enhancing slightly more than normal
myocardium, were missed because of the extreme contrast of
the image.
Hyperenhancement in the peri-infarction zone following
Gd-DTPA administration was particularly reported within
the first 24 h following induction of MI (12). Our data do
not exclude the possibility of enhancement in a peripheral
region surrounding the infarction, which resolves by 48 h.
However, any difference in regional enhancement between
the two contrast agents that can only be observed in this
early postinfarction period will be of merely limited clinical
relevance. Logistical difficulties associated with performing
such an exam in the frequently unstable postinfarction phase
are augmented by a time delay of six or more hours required
by necrosis-specific contrast agents to be sufficiently elimi-
nated from the blood pool and accumulate within the
necrotic myocardium.
To date there have been no data describing the enhance-
ment characteristics of necrosis-specific contrast agents in
CMI. Our data demonstrate that six-week-old CMIs do
not enhance with gadophrin-3, whereas hyperenhancement
on T1-weighted images following injection of extracellular
contrast agents is unimpaired. Thus, it appears that the
combination of extracellular and necrosis-specific contrast
agents will be helpful in the differentiation of acute from
chronic myocardial injuries.
Study limitations. This study has several limitations. First,
only nonreperfused MIs were investigated. Reperfused in-
farctions may present with totally different patterns of
enhancement. Second, as we aimed to image acute infarc-
tions using two different contrast agents without a time
delay, we had to compare gadophrin-3 and gadophrin-3
plus Magnevist-enhanced images. The absolute size of the
infarction defined only by Magnevist enhancement could
not be measured. However, overestimation of the infarct by
Gd-DTPA could be excluded. Finally, comparison of in-
vivo and postmortem images had to be performed using
anatomical landmarks, because no epicardial markers were
used in this infarct model.
CONCLUSIONS
Although some controversies persist, it can be concluded
that imaging of delayed enhancement using extracellular
contrast agents is a reliable tool for assessment of infarction
size in AMI and CMI. In contrast to using Magnevist
alone, the combination of gadophrin-3 and Magnevist can
distinguish AMI and CMI because CMIs do not enhance
with the necrosis-specific agent gadophrin-3.
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